Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

US firm in market allegations

Lea Paterson
Friday 02 April 1999 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

OECHSLE International Advisers, a Boston-based money manager, has admitted to being the US company embroiled in market manipulation allegations in London.

A company spokesman said the Securities and Exchange Commission, the US financial watchdog, was investigating whether an Oechsle portfolio manager had attempted to manipulate the price of a London stock via the investment banks Morgan Stanley and ABN Amro.

Oechsle declined to name the fund manager involved, who has been placed on administrative leave, but sources close to the investigation suggested it was Andrew Parlin, an employee of the company since 1988.

Morgan Stanley and ABN Amro were fined a total of pounds 350,000 earlier this week for accepting instructions from a previously unnamed US customer to move a share price on the London Stock Exchange.

The Exchange has declined either to provide details of the dealings or to identify the affected stock. An Exchange spokesman refused yesterday to comment on reports that named the stock as British Biotech.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in